Ipamorelin Research: Selective Ghrelin-Receptor Signaling

Ipamorelin is a small synthetic pentapeptide that acts at the growth-hormone secretagogue receptor (GHS-R1a) — the same receptor the hormone ghrelin binds. It's studied as a “growth-hormone secretagogue”: a compound that prompts the pituitary to release growth hormone. Its claim to fame in the literature is selectivity. Educational research summary only; no human or veterinary use is described.

The “first selective” secretagogue

The foundational paper introduced ipamorelin as the first growth-hormone secretagogue with selectivity for GH release — meaning, in their models, it stimulated growth hormone without the increases in cortisol and prolactin seen with earlier secretagogues (Raun et al., Eur J Endocrinol, 1998). [1] That clean profile is the single most-cited reason researchers reach for it.

A ghrelin mimetic

Because it binds GHS-R1a, ipamorelin is studied as a ghrelin mimetic, and research has examined whether GH-releasing peptides act through ghrelin-receptor pathways (Ahnfelt-Rønne, Nowak & Olsen, Endocrine, 2001). [2] This connects it to a broader literature on appetite and gut-motility signaling that runs through the same receptor.

Bone and tissue models

Beyond GH release itself, animal work has looked at downstream effects — for example, the secretagogue's influence in bone-research models (Andersen et al., Growth Horm IGF Res, 2001). [3] As always, these are controlled preclinical observations.